Synergy CHC expands FOCUSfactor to UAE, Turkey

Synergy CHC (SNYR) has expanded its international licensing deal with Gravity Pharma, adding Turkey alongside the United Arab Emirates UAE for exclusive distribution of FOCUSfactor. This move brings total upfront licensing revenue to $2M, with additional performance-based royalties tied to product sales across both high-growth markets. The UAE-Turkey licensing model allows Synergy to scale the FOCUSfactor brand-including brain health supplements, cognitive beverages, and energy shots-without diluting ownership or diverting U.S.-based operational focus. Synergy retains 100% ownership and global IP, with performance-based royalties driving long-term upside.